Cargando…
Carfilzomib-Induced Tumor Lysis Syndrome and Biventricular Heart Failure in a Patient With Multiple Myeloma
Carfilzomib is a proteasome inhibitor (PI) used in multiple myeloma (MM) that is resistant to other therapies. Despite its efficacy and potency, carfilzomib has been associated with kidney injuries, cardiovascular toxic effects, and hematological adverse events. Tumor lysis syndrome (TLS) following...
Autores principales: | Azad, Farhan, Moyer, Ross, Miranda, Clive J, Gravina, Matthew |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9907735/ https://www.ncbi.nlm.nih.gov/pubmed/36779143 http://dx.doi.org/10.7759/cureus.33538 |
Ejemplares similares
-
Eustachian Valve Endocarditis in a Patient With Charcot-Marie-Tooth Disease
por: Moyer, Ross, et al.
Publicado: (2023) -
A Case of Symptomatic Supratherapeutic International Normalized Ratio on Rivaroxaban
por: Khidhir, Angela, et al.
Publicado: (2023) -
A Case Report of Dilated Biventricular Heart Failure from Hyperthyroidism: A Rare Presentation
por: Ali, Rizwan, et al.
Publicado: (2018) -
Mechanisms and Potential Treatment Options of Heart Failure in Patients With Multiple Myeloma
por: Proskuriakova, Ekaterina, et al.
Publicado: (2021) -
Decompensated Heart Failure as the Initial Presentation of Multiple Myeloma: A Case Report
por: Maisuradze, Nodari, et al.
Publicado: (2022)